Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.

Cancer
Sandip H PatelMing Yin

Abstract

Some cancer patients who are diagnosed with thromboembolism may require dual treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors (low-molecular-weight heparin [LMWH] or direct oral anticoagulants [DOACs]). However, to the authors' knowledge, the safety of such combinations has not been well characterized. Patients with advanced cancer who were treated with concurrent VEGFR TKIs and factor Xa inhibitors between 2010 and 2018 at The Ohio State University Comprehensive Cancer Center were included. Charts were reviewed retrospectively for clinically significant bleeding events occurring during concurrent treatment compared with those occurring during factor Xa inhibitor therapy alone, using each patient as their own control. The Fisher exact test was used to compare distribution of bleeding severities. The Cox proportional hazards model was used to compare bleeding risk between groups. Among 86 patients, there were 29 clinically significant bleeding events (including 8 major bleeding events) reported during concurrent treatment and 17 events (including 4 major bleeding events) reported during factor Xa inhibitor therapy alone over a median follow-up of 63 day...Continue Reading

References

Jul 11, 2003·The New England Journal of Medicine·Agnes Y Y LeeUNKNOWN Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Veno
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Mar 1, 2007·Vascular Health and Risk Management·Naoyo NishidaMasamichi Kojiro
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
Apr 26, 2008·Neuro-oncology·Phioanh Leia NghiemphuTimothy F Cloughesy
May 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shusheng WangEric N Olson
Oct 19, 2010·Cancer Research·Farbod ShojaeiJames G Christensen
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Dec 17, 2014·International Journal of Epidemiology·Leila D A F Amorim, Jianwen Cai
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Agnes Y Y LeeUNKNOWN CATCH Investigators
Feb 9, 2016·Lancet·Gordon C JaysonAdrian L Harris
Feb 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriMichael J Morris
Jul 12, 2017·Cancer Chemotherapy and Pharmacology·Bo LiuGuang-Hui Wei
Dec 13, 2017·The New England Journal of Medicine·Gary E RaskobUNKNOWN Hokusai VTE Cancer Investigators
Apr 29, 2018·Journal of the American Society of Hypertension : JASH·Rhian M TouyzJoerg Herrmann
May 11, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Annie M YoungMark Levine
Jul 6, 2018·Journal of Thrombosis and Haemostasis : JTH·B M E TullemansM J E Kuijpers
Aug 3, 2018·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Carsten Grüllich
Mar 31, 2020·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN Caravaggio Investigators

❮ Previous
Next ❯

Citations

Nov 9, 2021·Current Oncology Reports·Ernesto RossiPaolo Andrea Zucali

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.